• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

对先前使用含第二代NS5A抑制剂、索磷布韦+格卡瑞韦/哌仑他韦和利巴韦林的方案治疗16 - 24周失败的慢性丙型肝炎3a型和肝硬化患者进行再治疗。

Retreatment of patients with chronic hepatitis C, subtype 3a, and cirrhosis, who previously failed a regimen containing second-generation NS5A inhibitors with sofosbuvir + glecaprevir/pibrentasvir and ribavirin for 16-24 weeks.

作者信息

Fedorchenko Sergii V, Klimenko Zhanna, Martynovich Tatiana, Solianyk Iryna, Suprunenko Tatiana

机构信息

Department of Viral Hepatitis and AIDS, The L.V. Gromashevskyi Institute of Epidemiology and Infectious Disease, Kyiv, Ukraine.

出版信息

J Virol. 2025 Feb 25;99(2):e0184324. doi: 10.1128/jvi.01843-24. Epub 2025 Jan 22.

DOI:10.1128/jvi.01843-24
PMID:39840947
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11852967/
Abstract

The outcomes of retreatment patients infected with hepatitis C virus genotype 3, cirrhosis, with velpatasvir may be affected by treatment failure with velpatasvir. The efficacy of SOF+GLE/PIB+RIB 16-24 weeks of treatment has been shown. The presence of NS5A resistance-associated substitution mutations, including Y93H, and the number and regimens of the past failed therapy do not influence the likelihood of achieving sustained virological response. When velpatasvir treatment fails, pibrentasvir should be used as the first choice for retreatment.

摘要

感染丙型肝炎病毒3型、肝硬化的患者接受维帕他韦再治疗的结果可能会受到维帕他韦治疗失败的影响。已显示索磷布韦+ glecaprevir / pibrentasvir治疗16 - 24周的疗效。包括Y93H在内的NS5A耐药相关替代突变的存在，以及过去失败治疗的次数和方案，均不影响实现持续病毒学应答的可能性。当维帕他韦治疗失败时，应将pibrentasvir作为再治疗的首选药物。

相似文献

1
Retreatment of patients with chronic hepatitis C, subtype 3a, and cirrhosis, who previously failed a regimen containing second-generation NS5A inhibitors with sofosbuvir + glecaprevir/pibrentasvir and ribavirin for 16-24 weeks.对先前使用含第二代NS5A抑制剂、索磷布韦+格卡瑞韦/哌仑他韦和利巴韦林的方案治疗16 - 24周失败的慢性丙型肝炎3a型和肝硬化患者进行再治疗。
J Virol. 2025 Feb 25;99(2):e0184324. doi: 10.1128/jvi.01843-24. Epub 2025 Jan 22.
2
Real-life effectiveness of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients previously treated with sofosbuvir/velpatasvir or glecaprevir/pibrentasvir.索磷布韦/维帕他韦/沃西拉韦在既往接受索磷布韦/维帕他韦或格卡瑞韦/哌仑他韦治疗的丙型肝炎患者中的真实世界疗效。
Aliment Pharmacol Ther. 2024 Jul;60(2):201-211. doi: 10.1111/apt.18020. Epub 2024 May 2.
3
Effectiveness of retreatment with ombitasvir/paritaprevir/ritonavir and dasabuvir+sofosbuvir+ribavirin in patients with chronic hepatitis C, subtype 1b, and cirrhosis, who failed previous treatment with first- and second-generation NS5A inhibitors.对于使用第一代和第二代 NS5A 抑制剂治疗失败的慢性丙型肝炎 1b 型和肝硬化患者，使用奥比他韦/帕利他韦/利托那韦和达萨布韦/索磷布韦/利巴韦林进行再治疗的效果。
J Med Virol. 2021 Aug;93(8):4975-4981. doi: 10.1002/jmv.26935. Epub 2021 Mar 25.
4
High efficacy of resistance-guided retreatment of HCV patients failing NS5A inhibitors in the real world.在真实世界中，对失败于 NS5A 抑制剂的 HCV 患者进行耐药指导的再治疗具有很高的疗效。
J Hepatol. 2019 Nov;71(5):876-888. doi: 10.1016/j.jhep.2019.06.022. Epub 2019 Jul 4.
5
NS5A-P32 deletion as a factor involved in virologic failure in patients receiving glecaprevir and pibrentasvir.NS5A-P32 缺失是导致接受 glecaprevir 和 pibrentasvir 治疗的患者病毒学失败的一个因素。
J Gastroenterol. 2019 May;54(5):459-470. doi: 10.1007/s00535-018-01543-9. Epub 2019 Jan 5.
6
An Increase in the Prevalence of Clinically Relevant Resistance-Associated Substitutions in Four Direct-Acting Antiviral Regimens: A Study Using GenBank HCV Sequences.四种直接作用抗病毒方案中临床相关耐药相关替代位点流行率的增加：一项使用GenBank HCV序列的研究
Pathogens. 2024 Aug 9;13(8):674. doi: 10.3390/pathogens13080674.
7
Sofosbuvir/Velpatasvir Plus Ribavirin Combination Therapy for Patients with Hepatitis C Virus Genotype 1a, 2a, or 3b after Glecaprevir/Pibrentasvir Therapy Failed.索磷布韦/维帕他韦联合利巴韦林治疗格卡瑞韦哌仑他韦治疗失败的 HCV 基因 1a、2a 或 3b 型患者
Intern Med. 2021 Nov 1;60(21):3441-3445. doi: 10.2169/internalmedicine.7028-21. Epub 2021 May 22.
8
Deferred treatment with sofosbuvir-velpatasvir-voxilaprevir for patients with chronic hepatitis C virus who were previously treated with an NS5A inhibitor: an open-label substudy of POLARIS-1.在 POLARIS-1 开放性标签子研究中，对先前接受过 NS5A 抑制剂治疗的慢性丙型肝炎病毒患者进行索磷布韦-维帕他韦-沃西拉韦的延迟治疗。
Lancet Gastroenterol Hepatol. 2018 Aug;3(8):559-565. doi: 10.1016/S2468-1253(18)30118-3. Epub 2018 May 31.
9
Direct Antivirals Can Achieve a Cure in All Patients With Chronic Hepatitis C due to Genotype 5: A French Multicentre Study.直接抗病毒药物可治愈所有基因型5所致慢性丙型肝炎患者：一项法国多中心研究
Liver Int. 2025 Apr;45(4):e16158. doi: 10.1111/liv.16158. Epub 2024 Nov 12.
10
No impact of resistance-associated substitutions on the efficacy of sofosbuvir, velpatasvir, and voxilaprevir for 12 weeks in HCV DAA-experienced patients.在 DAA 经治的 HCV 患者中，12 周内无耐药相关替换对索磷布韦、维帕他韦和沃维沙韦疗效的影响。
J Hepatol. 2018 Dec;69(6):1221-1230. doi: 10.1016/j.jhep.2018.07.023. Epub 2018 Aug 9.

本文引用的文献

1
Real-world effectiveness of voxilaprevir/velpatasvir/sofosbuvir in patients following DAA failure.伏西拉普瑞韦/维帕他韦/索磷布韦在直接抗病毒药物治疗失败患者中的真实世界有效性
JHEP Rep. 2024 Feb 7;6(3):100994. doi: 10.1016/j.jhepr.2023.100994. eCollection 2024 Mar.
2
Efficacy and safety of sofosbuvir/velpatasvir with or without ribavirin in hepatitis C genotype 3 compensated cirrhosis: A meta-analysis.索磷布韦/维帕他韦联合或不联合利巴韦林治疗丙型肝炎基因3型代偿期肝硬化的疗效与安全性：一项荟萃分析。
World J Hepatol. 2022 Jun 27;14(6):1248-1257. doi: 10.4254/wjh.v14.i6.1248.
3
Retreatment for hepatitis C virus direct acting antiviral therapy virological failure in primary and tertiary settings: the REACH-C cohort.丙型肝炎病毒直接抗病毒治疗在初级和三级医疗机构中病毒学失败后的再治疗：REACH-C队列研究
J Viral Hepat. 2022 May 18;29(8):661-76. doi: 10.1111/jvh.13705.
4
Safety and Effectiveness Using 8 Weeks of Glecaprevir/Pibrentasvir in HCV-Infected Treatment-Naïve Patients with Compensated Cirrhosis: The CREST Study.使用 8 周格卡匹韦/哌仑他韦治疗初治代偿期肝硬化丙型肝炎病毒感染患者的安全性和有效性：CREST 研究。
Adv Ther. 2022 Jul;39(7):3146-3158. doi: 10.1007/s12325-022-02158-6. Epub 2022 May 11.
5
The Role of RASs /RVs in the Current Management of HCV.RASs /RVs 在 HCV 现行管理中的作用。
Viruses. 2021 Oct 18;13(10):2096. doi: 10.3390/v13102096.
6
Using host genetics to infer the global spread and evolutionary history of HCV subtype 3a.利用宿主遗传学推断丙型肝炎病毒3a亚型的全球传播及进化史。
Virus Evol. 2021 Jul 9;7(2):veab065. doi: 10.1093/ve/veab065. eCollection 2021.
7
Real world SOF/VEL/VOX retreatment outcomes and viral resistance analysis for HCV patients with prior failure to DAA therapy.真实世界中，对于曾对直接作用抗病毒药物（DAA）治疗失败的 HCV 患者，SOF/VEL/VOX 再治疗的结局和病毒耐药性分析。
J Viral Hepat. 2021 Sep;28(9):1256-1264. doi: 10.1111/jvh.13549. Epub 2021 Jun 8.
8
Virological Factors Associated with Failure to the Latest Generation of Direct Acting Agents (DAA) and Re-Treatment Strategy: A Narrative Review.与最新一代直接作用抗病毒药物（DAA）失败相关的病毒学因素及再治疗策略：叙述性综述。
Viruses. 2021 Mar 8;13(3):432. doi: 10.3390/v13030432.
9
Real-world re-treatment outcomes of direct-acting antiviral therapy failure in patients with chronic hepatitis C.直接作用抗病毒治疗失败的慢性丙型肝炎患者的真实世界再治疗结局。
J Med Virol. 2021 Aug;93(8):4982-4991. doi: 10.1002/jmv.26971. Epub 2021 Apr 13.
10
Treatment failure with DAA therapy: Importance of resistance.直接抗病毒药物（DAA）治疗失败：耐药性的重要性
J Hepatol. 2021 Jun;74(6):1472-1482. doi: 10.1016/j.jhep.2021.03.004. Epub 2021 Mar 12.